POST Online Media Lite Edition


Third time's not a charm: Depomed rejects Horizon Pharma again

Staff writer |
Depomed rejected Horizon Pharma's takeover bid for the third time, reiterating that the offer undervalued the company.

Article continues below

Depomed said Horizon Pharma's latest all-stock bid had a current value of $30 per share, or about $1.81 billion, lower than Horizon's previous offer of $33.

Horizon Pharma said last Thursday it would offer 0.95 Horizon Pharma shares for every Depomed share. It had also said it could alternatively offer Depomed shareholders $32.50 in cash and stock.

Horizon Pharma first approached Depomed in May and went hostile with its offer in July after being rejected. Depomed adopted a poison pill to stave off the bid.

What to read next

Horizon Pharma raises offer for Depomed to $33 per share
Horizon Pharma goes hostile after Depomed, $3 billion deal rejected
Depomed rejects proposal from Horizon Pharma